Vaccentis, a biotech company based in Zurich, Switzerland, has announced a strategic partnership with TrueMed, a leading commercialization partner, to accelerate the development of their therapeutic protein-based tumor vaccines. The agreement, signed on Thursday October 9, 2025, aims to drive the strategic and operational development of Vaccentis, with a focus on their lead vaccine candidate VCC…
